Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 13/20 | 0.52 |
| ▸ | PDE4A | P27815 | 2/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | PDE8A | O60658 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.43 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12321567 | 0.91 | PDE5A (0.53) | PDE5APDE4APDE2APDE8APDE3B | |
| SCHEMBL2362857 | 0.86 | PDE4A (0.49) | PDE5APDE4APDE2APDE8APDE3B | |
| SCHEMBL14837599 | 0.86 | PDE4A (0.52) | PDE5APDE4APDE2APDE8APDE3B | |
| SCHEMBL2416980 | 0.84 | PDE4A (0.58) | PDE5APDE4APDE2APDE8APDE3B | |
| SCHEMBL2362342 | 0.83 | PDE4A (0.41) | PDE5APDE4APDE2APDE8APDE3B | |
| SCHEMBL2361465 | 0.82 | PDE4A (0.60) | PDE5APDE4APDE2APDE8APDE3B | |
| SCHEMBL2362351 | 0.80 | PDE5A (0.49) | PDE5APDE4A | |
| SCHEMBL194617 | 0.73 | PDE5A (0.79) | PDE5APDE4A | |
| SCHEMBL2362440 | 0.71 | PDE4A (0.64) | PDE5APDE4APDE2APDE8APDE3B | |
| SCHEMBL2412384 | 0.69 | PDE4A (0.58) | PDE5APDE4APDE2APDE8APDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9763948-B2 | PDE1 inhibitory compounds and methods | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| EP-2358204-B1 | 4,5,7,8-tetrahydro-4-oxo-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors. | INTRA CELLULAR THERAPIES INC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2358204-B1 | 4,5,7,8-tetrahydro-4-oxo-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors. | INTRA CELLULAR THERAPIES INC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20150072965-A1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150072965-A1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150072965-A1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2015-03-12 | — | — | US | disclosed |
| US-20140148421-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148421-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148421-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8664207-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664207-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130331363-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2013-12-12 | — | — | US | disclosed |
| EP-2576551-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011153138-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2011-12-08 | — | — | WO | disclosed |
| US-20110237561-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-09-29 | — | — | US | disclosed |
| US-20110237561-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-09-29 | — | — | US | disclosed |
| US-20110237561-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-09-29 | — | — | US | disclosed |
| EP-2358204-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010065148-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065148-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148421-A1 | ORGANIC COMPOUNDS | TPMT, TYMS, THPO | PDE5A 1584/4885PDE4A 989/4885PDE2A 1835/4885 |
| US-20130331363-A1 | ORGANIC COMPOUNDS | TPMT, TYMS, THPO | PDE5A 2313/4885PDE4A 991/4885PDE2A 2389/4885 |
| US-20150072965-A1 | ORGANIC COMPOUNDS | TPMT, TYMS, THPO | PDE5A 1584/4885PDE4A 989/4885PDE2A 1835/4885 |
| US-20110237561-A1 | ORGANIC COMPOUNDS | TPMT, TYMS, THPO | PDE5A 1584/4885PDE4A 989/4885PDE2A 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.